Nintedanib (Ofev) treatment significantly slowed disease progression versus placebo in a phase III trial involving patients with fibrosing interstitial lung diseases (ILD) other than idiopathic pulmonary fibrosis (IPF), researchers reported.
In the INBUILD trial, patients with fibrosing ILD treated with nintedanib had an adjusted rate of decline in forced vital capacity (FVC) of -80.8 ml per year versus -187.8 ml per year in the placebo group (difference of 107 ml per year, 95% CI 65.4-148.5, P<0.001), reported Keven K. Brown, MD, of National Jewish Health in Denver, and colleagues.
Cancelled ILD appointments 
Side effects of Nintedanib
Patient survey - IPF/ILD 
